Literature DB >> 20884790

Therapeutic angiogenesis for cardiovascular disease: biological context, challenges, prospects.

Ian Zachary1, Robert D Morgan.   

Abstract

Since the discovery of vascular endothelial growth factor (VEGF), therapeutic angiogenesis has attracted interest as an alternative treatment for ischaemic heart and peripheral disease. In parallel, the view has also gained ground that angiogenesis has an important role in the pathogenesis of atherosclerotic disease and its clinical sequelae. These conflicting perspectives have both been based on a large quantity of preclinical data obtained from mainly small rodent models of disease. However, in recent years further research and the results of clinical trials of pro-angiogenic and anti-angiogenic treatments have provided new insights into the impact of VEGF and other angiogenesis-based approaches on human health and disease. This review discusses therapeutic angiogenesis in the light of recent scientific advances and clinical evidence, and considers the future challenges and prospects for therapeutic angiogenesis.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20884790     DOI: 10.1136/hrt.2009.180414

Source DB:  PubMed          Journal:  Heart        ISSN: 1355-6037            Impact factor:   5.994


  47 in total

1.  Sequential delivery of angiogenic growth factors improves revascularization and heart function after myocardial infarction.

Authors:  Hassan K Awada; Noah R Johnson; Yadong Wang
Journal:  J Control Release       Date:  2015-03-31       Impact factor: 9.776

Review 2.  Receptor tyrosine kinase-mediated angiogenesis.

Authors:  Michael Jeltsch; Veli-Matti Leppänen; Pipsa Saharinen; Kari Alitalo
Journal:  Cold Spring Harb Perspect Biol       Date:  2013-09-01       Impact factor: 10.005

3.  Dual delivery of vascular endothelial growth factor and hepatocyte growth factor coacervate displays strong angiogenic effects.

Authors:  Hassan K Awada; Noah R Johnson; Yadong Wang
Journal:  Macromol Biosci       Date:  2014-01-23       Impact factor: 4.979

Review 4.  Targeted gene therapy for the treatment of heart failure.

Authors:  Kleopatra Rapti; Antoine H Chaanine; Roger J Hajjar
Journal:  Can J Cardiol       Date:  2011 May-Jun       Impact factor: 5.223

5.  Clonal and diverse: revisiting cardiac endothelial cells after myocardial infarction.

Authors:  David Rohde; Matthias Nahrendorf
Journal:  Eur Heart J       Date:  2019-08-07       Impact factor: 29.983

6.  Endothelial HIF-2α regulates murine pathological angiogenesis and revascularization processes.

Authors:  Nicolas Skuli; Amar J Majmundar; Bryan L Krock; Rickson C Mesquita; Lijoy K Mathew; Zachary L Quinn; Anja Runge; Liping Liu; Meeri N Kim; Jiaming Liang; Steven Schenkel; Arjun G Yodh; Brian Keith; M Celeste Simon
Journal:  J Clin Invest       Date:  2012-03-19       Impact factor: 14.808

7.  Pathway analysis with next-generation sequencing data.

Authors:  Jinying Zhao; Yun Zhu; Eric Boerwinkle; Momiao Xiong
Journal:  Eur J Hum Genet       Date:  2014-07-02       Impact factor: 4.246

8.  Matrix composition and mechanics direct proangiogenic signaling from mesenchymal stem cells.

Authors:  Amr A Abdeen; Jared B Weiss; Junmin Lee; Kristopher A Kilian
Journal:  Tissue Eng Part A       Date:  2014-05-12       Impact factor: 3.845

Review 9.  Clinical translation of controlled protein delivery systems for tissue engineering.

Authors:  Kara L Spiller; Gordana Vunjak-Novakovic
Journal:  Drug Deliv Transl Res       Date:  2015-04       Impact factor: 4.617

Review 10.  Cardiovascular gene therapy for myocardial infarction.

Authors:  Maria C Scimia; Anna M Gumpert; Walter J Koch
Journal:  Expert Opin Biol Ther       Date:  2013-12-16       Impact factor: 4.388

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.